Matches in SemOpenAlex for { <https://semopenalex.org/work/W2767938051> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2767938051 endingPage "S2278" @default.
- W2767938051 startingPage "S2278" @default.
- W2767938051 abstract "Apatinib is a specific tyrosine kinase inhibitor that targets VEGFR-2. Treatment of primary lung cancer patients with apatinib is a new promising paradigm. In addition to hypertension and hand-foot syndrome, tumor cavitation and increase in CEA value are frequently noted in these patients. However, there are limited literatures regarding whether they could be used as potential biomarkers for anti-angiogenic therapy. This study was to evaluate the frequency and clinical outcome of primary lung cancer patients who developed tumor cavitation or showed increase in CEA value following apatinib treatment. This was a retrospective analysis of primary lung cancer patients treated with apatinib in the Affiliated Hospital of Qiingdao University between 2/1/2015 and 5/19/2017. Clinical data were retrieved from medical records, and chest imaging findings were documented. Survival data were analyzed with Kaplan-Meier estimates and compared with log-rank test. A total of 38 primary lung cancer patients received oral apatinib as the third-line or beyond therapy at an initial dose of 250 mg (n=37) or 500 mg (n=1) per day. During treatment, tumor cavitation was developed in 20 of the 38 (52.6%) patients. No significant difference was observed between patients with and without cavity formation in age, gender, tumor histology, tumor stage, history of pulmonary surgery and apatinib typical adverse events. Cavity formation was accompanied with temporary increase in CEA value (65.0% vs. 5.6% in patients with and without cavitary lesions; P=0.0001). The progression-free survival (PFS) of patients with cavitary lesions was 11.25 (95% CI, 10.16-13.64) months, which was significantly longer compared with those without (6.11 [95% CI, 6.01-6.71] months; P<0.0001). Besides, patients with a temporary increase in CEA had a longer PFS than those without (10.64 [95% CI, 10.09-14.14] vs. 6.14 [95% CI, 6.07-8.13] months), but the difference was not significant (P=0.0703). Cavitation formation induced by apatinib is common in primary lung cancer patients, and is not correlated with age, gender, tumor histology, tumor stage, history of pulmonary surgery and common adverse events. Cavitation might have significant effects on the temporary increase in CEA value and PFS prognosis." @default.
- W2767938051 created "2017-11-17" @default.
- W2767938051 creator A5008508108 @default.
- W2767938051 creator A5011560173 @default.
- W2767938051 creator A5029794686 @default.
- W2767938051 creator A5048800314 @default.
- W2767938051 creator A5051739465 @default.
- W2767938051 creator A5058382693 @default.
- W2767938051 creator A5072066822 @default.
- W2767938051 creator A5074344662 @default.
- W2767938051 creator A5075499662 @default.
- W2767938051 date "2017-11-01" @default.
- W2767938051 modified "2023-09-26" @default.
- W2767938051 title "P3.03-014 Tumor Cavitation in Patients with Primary Lung Cancer Following Apatinib Treatment" @default.
- W2767938051 doi "https://doi.org/10.1016/j.jtho.2017.09.1640" @default.
- W2767938051 hasPublicationYear "2017" @default.
- W2767938051 type Work @default.
- W2767938051 sameAs 2767938051 @default.
- W2767938051 citedByCount "0" @default.
- W2767938051 crossrefType "journal-article" @default.
- W2767938051 hasAuthorship W2767938051A5008508108 @default.
- W2767938051 hasAuthorship W2767938051A5011560173 @default.
- W2767938051 hasAuthorship W2767938051A5029794686 @default.
- W2767938051 hasAuthorship W2767938051A5048800314 @default.
- W2767938051 hasAuthorship W2767938051A5051739465 @default.
- W2767938051 hasAuthorship W2767938051A5058382693 @default.
- W2767938051 hasAuthorship W2767938051A5072066822 @default.
- W2767938051 hasAuthorship W2767938051A5074344662 @default.
- W2767938051 hasAuthorship W2767938051A5075499662 @default.
- W2767938051 hasBestOaLocation W27679380511 @default.
- W2767938051 hasConcept C121608353 @default.
- W2767938051 hasConcept C126322002 @default.
- W2767938051 hasConcept C141071460 @default.
- W2767938051 hasConcept C143998085 @default.
- W2767938051 hasConcept C146357865 @default.
- W2767938051 hasConcept C151730666 @default.
- W2767938051 hasConcept C2776256026 @default.
- W2767938051 hasConcept C2778820342 @default.
- W2767938051 hasConcept C2779013556 @default.
- W2767938051 hasConcept C2780283643 @default.
- W2767938051 hasConcept C2780668389 @default.
- W2767938051 hasConcept C71924100 @default.
- W2767938051 hasConcept C86803240 @default.
- W2767938051 hasConcept C90924648 @default.
- W2767938051 hasConceptScore W2767938051C121608353 @default.
- W2767938051 hasConceptScore W2767938051C126322002 @default.
- W2767938051 hasConceptScore W2767938051C141071460 @default.
- W2767938051 hasConceptScore W2767938051C143998085 @default.
- W2767938051 hasConceptScore W2767938051C146357865 @default.
- W2767938051 hasConceptScore W2767938051C151730666 @default.
- W2767938051 hasConceptScore W2767938051C2776256026 @default.
- W2767938051 hasConceptScore W2767938051C2778820342 @default.
- W2767938051 hasConceptScore W2767938051C2779013556 @default.
- W2767938051 hasConceptScore W2767938051C2780283643 @default.
- W2767938051 hasConceptScore W2767938051C2780668389 @default.
- W2767938051 hasConceptScore W2767938051C71924100 @default.
- W2767938051 hasConceptScore W2767938051C86803240 @default.
- W2767938051 hasConceptScore W2767938051C90924648 @default.
- W2767938051 hasIssue "11" @default.
- W2767938051 hasLocation W27679380511 @default.
- W2767938051 hasOpenAccess W2767938051 @default.
- W2767938051 hasPrimaryLocation W27679380511 @default.
- W2767938051 hasRelatedWork W1985488488 @default.
- W2767938051 hasRelatedWork W2283064216 @default.
- W2767938051 hasRelatedWork W2621658602 @default.
- W2767938051 hasRelatedWork W2978946191 @default.
- W2767938051 hasRelatedWork W3202233258 @default.
- W2767938051 hasRelatedWork W3203751587 @default.
- W2767938051 hasRelatedWork W4292449075 @default.
- W2767938051 hasRelatedWork W4293029332 @default.
- W2767938051 hasRelatedWork W4309213401 @default.
- W2767938051 hasRelatedWork W2549308358 @default.
- W2767938051 hasVolume "12" @default.
- W2767938051 isParatext "false" @default.
- W2767938051 isRetracted "false" @default.
- W2767938051 magId "2767938051" @default.
- W2767938051 workType "article" @default.